Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib.
Helen Gogas
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche
Honoraria - Bristol-Myers Squibb
Dirk Schadendorf
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Merck
Reinhard Dummer
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Cephalon; GlaxoSmithKline; MSD; Novartis; Roche
Claus Garbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Celeste Lebbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Paul D. Nathan
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis; Pfizer
Andrew Mark Haydon
No relevant relationships to disclose
Dimitris Bafaloukos
Consultant or Advisory Role - Bristol-Myers Squibb; Roche
Honoraria - Bristol-Myers Squibb
Caroline Robert
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche